On September 30, 2021, Galderma celebrated its 25th anniversary of its Restylane line of hyaluronic acid fillers.
It has been 25 years since the launch of Galderma’s Restylane line of hyaluronic acid (HA) fillers in Europe.1
Since becoming the first HA filler approved by the FDA in 2003, Restylane’s portfolio has continued to grow with 13 dermal filler product approvals and launches. They offer 2 complementary gel technologies—Nasha and XpreHAn (globally referred to as the OBT technology (Optimal Balance Technology)—to help patient satisfaction.
In February 2021, the FDA approved Restylane Defyne for chin augmentation and correction for mild to moderate chin retrusion for adults over 21 years old and in June of this year, Resylane Contour was approved for cheek augmentation and correction of midface contour deficiencies in adults over the age of 21. It became the first and only product in the US to use proprietary XpresHAn technology for the cheeks, according to Galderma.
"The depth of experience from Restylane over the last 25 years has enabled us to build upon our expertise to innovate and develop new formulations and treatments," said Flemming Ørnskov, MD, MPH, chief executive officer at Galderma, Fort Worth, Texas. "With over 30 ongoing pipeline projects in aesthetics alone, we will continue to enhance our diverse and broad portfolio of sophisticated brands to advance dermatology for every skin story."
1. Restylane celebrates 25 years of natural-looking results with its signature line of hyaluronic acid fillers. Cision PR Newswire. Press release. Published September 30, 2021. Accessed October 13, 2021. https://www.prnewswire.com/news-releases/restylane-celebrates-25-years-of-natural-looking-results-with-its-signature-line-of-hyaluronic-acid-fillers-301388779.html